Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
Pei‐Shan Wu, Miao‐Hsia Lin, Jye‐Chian Hsiao, et al.
Molecular & Cellular Proteomics (2023) Vol. 22, Iss. 9, pp. 100624-100624
Open Access | Times Cited: 11

Showing 11 citing articles:

Unveiling the mechanisms and challenges of cancer drug resistance
Sameer Ullah Khan, Kaneez Fatima, Shariqa Aisha, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 86
β-Elemene Reverses Gefitinib Resistance in NSCLC Cells by Inhibiting lncRNA H19-Mediated Autophagy
Ruonan Zhang, Yintao Zheng, Qianru Zhu, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 626-626
Open Access | Times Cited: 4
Single-Cell RNA Sequencing in Unraveling Acquired Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: New Perspectives
Peng Lin, Siyou Deng, Jinjie Li, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1483-1483
Open Access
Design, synthesis and biological evaluation of 2H-[1,4]oxazino-[2,3-f]quinazolin derivatives as potential EGFR inhibitors for Non-small cell lung cancer
Lin Huang, Ying Zhang, Peng Liu, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Facile construction of gefitinib‐loaded zeolitic imidazolate framework nanocomposites for the treatment of different lung cancer cells
Kalaivani Aiyasamy, Malathi Ramasamy, Abdurahman Hajinur Hirad, et al.
Biotechnology and Applied Biochemistry (2024) Vol. 71, Iss. 4, pp. 896-908
Closed Access | Times Cited: 3
Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?
Ahmed M. Elshazly, Jingwen Xu, Nebras Y. Melhem, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 2989-2989
Open Access | Times Cited: 3
Extending the Coverage of Lys-C/Trypsin-Based Bottom-up Proteomics by Cysteine S-Aminoethylation
Ryota Tomioka, Ayana Tomioka, Kosuke Ogata, et al.
Journal of the American Society for Mass Spectrometry (2024) Vol. 35, Iss. 2, pp. 386-396
Closed Access | Times Cited: 1
Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis
Hanyu Ni, Zilan Wang, Yanbing Tang, et al.
Cell Biology International (2024) Vol. 48, Iss. 10, pp. 1450-1462
Closed Access
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Brian J. Thomas, Sania Zafar Awan, Trupti Joshi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
O. O. Kovalov, O. P. Tolok, K. O. Kovalov
Pathologia (2024) Vol. 21, Iss. 1, pp. 84-88
Open Access
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
Brian J. Thomas, Sania Zafar Awan, Trupti Joshi, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
Page 1

Scroll to top